P/E at 34.04 vs Industry's 31.26: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Industry Norms

The current P/E of Sun Pharmaceutical Industries Ltd stands at 34.04, representing a 9% premium over the industry average of 31.26. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers in the Pharmaceuticals & Biotechnology sector. Such a valuation can imply expectations of superior earnings growth or a perception of lower risk compared to the industry average. However, the premium is not excessive, indicating a balanced market view rather than exuberance. Sun Pharmaceutical Industries Ltd’s market capitalisation of ₹4,13,285 crores firmly places it in the large-cap category, reinforcing its stature within the sector.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns across multiple timeframes reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a modest gain of 2.87%, underperforming the Sensex’s 4.11% rise. However, the short-term picture is more encouraging: the stock has outperformed the Sensex over three months, declining only -1.38% compared to the benchmark’s -8.20%. This relative resilience in the recent quarter contrasts with the broader market weakness and may reflect company-specific factors or sector rotation dynamics. Year-to-date, the stock has gained 1.01%, while the Sensex has fallen by -9.32%, further highlighting this divergence. Conversely, the one-month return of -3.43% slightly underperforms the Sensex’s -2.08%, indicating some short-term volatility. Sun Pharmaceutical Industries Ltd’s 1-day and 1-week performances have lagged the Sensex, with gains of 1.09% and 0.51% versus 3.57% and 5.67% respectively, suggesting recent market pressures. Sun Pharmaceutical Industries Ltd’s longer-term returns remain robust, with 3-year gains of 71.70% and 5-year gains of 182.79%, significantly outperforming the Sensex’s 29.16% and 55.35% over the same periods. This long-term outperformance contrasts with the more muted recent returns — is this a sign of a cyclical pause or a structural shift in momentum?

Moving Average Configuration: Mixed Technical Signals

The technical setup for Sun Pharmaceutical Industries Ltd reveals a nuanced picture. The stock is trading above its 5-day, 50-day, 100-day, and 200-day moving averages, signalling underlying strength and support at multiple longer-term levels. However, it remains below the 20-day moving average, indicating some short-term resistance or consolidation. This configuration often suggests a recent pullback within an overall uptrend or a tentative recovery after a short-term correction. The stock’s two-day consecutive gain, amounting to a 3.29% rise, supports the notion of a potential bounce. Yet, the underperformance relative to the sector’s 2.11% gain today and the Sensex’s stronger daily advance point to ongoing caution among investors. Is this a genuine recovery or a relief rally that will fade at the 20 DMA?

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has recorded a gain of 2.11% on the day, outperforming Sun Pharmaceutical Industries Ltd’s 1.09% advance. This suggests that while the sector is experiencing positive momentum, the stock is lagging slightly behind its peers in intraday performance. Over longer periods, the sector has shown mixed results with some stocks gaining, others flat, and a few declining, reflecting the varied impact of regulatory developments, patent expiries, and innovation cycles. The sector’s average P/E of 31.26 provides a useful benchmark for valuation comparisons, and Sun Pharmaceutical Industries Ltd’s premium valuation may be justified by its scale and historical earnings growth. How does the sector’s mixed performance influence the stock’s near-term outlook?

Rating Reassessment: Previously Hold, Now Updated

Sun Pharmaceutical Industries Ltd was previously rated Hold by MarketsMOJO before its rating was updated on 23 Feb 2026. The reassessment reflects a comprehensive four-parameter analysis incorporating valuation, financial trends, technical indicators, and quality metrics. The current Mojo Score of 72.0 supports a positive stance, though the exact rating is not disclosed. This update comes amid the stock’s mixed recent performance and modest valuation premium, suggesting a nuanced view of its prospects. What is the current rating for Sun Pharmaceutical Industries Ltd following this reassessment?

Collective Data Insights: Balancing Valuation and Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation premium with a mixed performance profile. The stock’s long-term returns have been impressive, significantly outpacing the Sensex over three and five years, yet recent short-term returns have been more subdued. The moving average configuration suggests a tentative recovery phase, with the stock supported by longer-term averages but facing resistance at the 20-day level. Sector performance remains positive but varied, adding complexity to the stock’s near-term outlook. The recent rating reassessment from Hold to a new status reflects these nuanced factors. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →